BioGX

16 articles about BioGX

• BioGX Expands PCR Test Menu at State Departments of Health

  1/11/2024

  BioGX, a leading global provider of easy molecular diagnostic solutions, is pleased to announce the test menu expansion support to Departments of Health with the addition of its Candida auris assay.

• Microbix & BioGX Collaborate on real-time PCR Assays & Controls

  12/7/2023

  Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, announces a collaboration with BioGX, Inc., a global provider of easy molecular diagnostic solutions.

• BioGX Candida Auris PCR Assay Global Adoption Accelerates

  7/24/2023

  BioGX, a global provider of easy molecular diagnostic solutions, announced accelerated adoption of their high performance Sample-Ready™ PCR assay* for detection of Candida auris, a rapidly spreading, hard to treat fungus with a growing presence in hospitals and long-term care facilities.

• BioGX Candida Auris PCR Assay Adoption Accelerates

  3/23/2023

  BioGX announced accelerated adoption of their high performance Sample-Ready™ PCR assay* for detection of Candida auris, a rapidly spreading, hard to treat fungus with a growing presence in hospitals and long-term care facilities.

• BioGX Ships First Batch of pixl(TM) Real-Time PCR Platform to US Laboratories

  2/28/2023

  BioGX has announced fulfillment of multiple initial orders for its portable pixl™ real-time PCR platform to customers across the U.S., with immediate plans to scale production to meet market demand.

• BioGX Launches 'pixl™' Portable qPCR Platform Ex-US With Expanded Test Menu for Infectious Diseases

  12/8/2022

  BioGX, a global provider of easy molecular diagnostic solutions since 2007, announced the Ex-US commercial release of its portable pixl™ qPCR real-time PCR platform for use with BioGX CE-IVD marked assays, enabling global access and complementing the recent US FDA EUA expanded use of Xfree™ COVID-19 Direct RT-PCR on the pixl.

• BioGX Expands FDA EUA with pixl™ Portable qPCR System for its Direct-Sample COVID-19 Assay

  11/10/2022

  BioGX announced that the US FDA has updated their original Direct Sample Xfree™ COVID-19 Emergency Use Authorization to increase the shelf-life of the assay reagent to 15 months and expand its use to additional real-time PCR platforms, including BioGX’s pixl™ real-time PCR platform.

• BioGX Launches CE-IVD Marked Multi-gene COVID-19 Point-of-Care Test at AACC

  7/27/2022

  BioGX, a global provider of easy molecular diagnostic solutions, announced the launch of a point-of-care (POC) CE-Marked, three gene multiplex COVID-19 test on its pixl platform.

• Cepheid and BioGX Announce Collaboration to Develop Monkeypox PCR Test for the GeneXpert® System

  6/27/2022

  Cepheid and BioGX today announced a collaboration between the two companies to deliver a PCR test for Monkeypox that will run on the GeneXpert system.

• BioGX COVID-19 Tests Detect Omicron SARS-CoV-2 Variant

  12/6/2021

  BioGX, a global provider of molecular diagnostic solutions, announced that the Omicron (B.1.1.529), the latest emerging SARS-CoV-2 variant of concern, will be detected by the portfolio of BioGX SARS-CoV-2 products that target the nucleocapsid (N-gene) and envelope (E-gene) for detection of the virus.

• BD, BioGX Announce FDA Emergency Use Authorization Submissions for New COVID-19 Diagnostics for Use in U.S.

  3/17/2020

  New Diagnostics Have Potential to Increase Capacity of COVID-19 Testing in U.S. by Thousands of Tests Per Day.

• BioGX and Launch Diagnostics Announce Distribution Partnership for U.K. and Ireland

  2/8/2018

  BioGX continues to expand its global presence with the announcement of a distribution partnership between BioGX's Amsterdam-based European subsidiary, BioGX B.V., and U.K.-based distributor, Launch Diagnostics.

• BioGX BV and AxonLab AG Announce Distribution Partnership

  2/6/2018

  The multi-year partnership, which began Jan. 1, 2018, represents a significant step in the United States-based company's overseas growth, as many of BioGX's products will now be available to a considerably broader customer base.

• BioGX Launches Four CE-Marked IVD Assays At The European Congress Of Clinical Microbiology And Infectious Diseases (ECCMID)

  4/24/2017

• BioGX Launches European Subsidiary To Expand Operations Into Europe

  4/24/2017

• BioGX Receives CE-IVD Mark For Influenza A, B And Respiratory Syncytial Virus Assay On The BD MAX System

  10/6/2016